SAN RAFAEL, Calif., Oct. 10, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced that the underwriters for its recently announced public offering of $680 million of its senior subordinated convertible notes consisting of $340 million 0.75% Senior Subordinated Convertible Notes due 2018 (the “2018 Notes”) and $340 million 1.50% Senior Subordinated Convertible Notes due 2020 (the “2020 Notes” and together with the 2018 Notes, the “Notes”) exercised in full their over-allotment option to purchase an additional $35 million principal amount of the 2018 Notes (the “Additional 2018 Notes”) and an additional $35 million principal amount of the 2020 Notes (the “Additional 2020 Notes,” and together with the Additional 2018 Notes, the “Additional Notes”).
Help employers find you! Check out all the jobs and post your resume.
